Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Echinacea formulations for acute respiratory infections
NCT03812900Phase 3Completed
- Sponsor
- A.Vogel
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of echinacea purpurea extract in respiratory tract infection (RTI), common cold and influenza-like illness (ILI) (4 arms), sponsored by A.Vogel. Primary endpoint: Time to remission from initial episodes at 10 days. Started Nov 2018; status: completed.
02
Drugs
echinacea purpurea extract
03
Conditions
respiratory tract infection (RTI)common coldinfluenza-like illness (ILI)
Beyond the preview
Go deeper on NCT03812900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812900.